177 related articles for article (PubMed ID: 34273111)
41. Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3.
Haacke A; Hartl FU; Breuer P
J Biol Chem; 2007 Jun; 282(26):18851-6. PubMed ID: 17488727
[TBL] [Abstract][Full Text] [Related]
42. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.
Nascimento-Ferreira I; Santos-Ferreira T; Sousa-Ferreira L; Auregan G; Onofre I; Alves S; Dufour N; Colomer Gould VF; Koeppen A; Déglon N; Pereira de Almeida L
Brain; 2011 May; 134(Pt 5):1400-15. PubMed ID: 21478185
[TBL] [Abstract][Full Text] [Related]
43. The Neuropathology of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.
Koeppen AH
Adv Exp Med Biol; 2018; 1049():233-241. PubMed ID: 29427106
[TBL] [Abstract][Full Text] [Related]
44. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.
Nguyen HP; Hübener J; Weber JJ; Grueninger S; Riess O; Weiss A
PLoS One; 2013; 8(4):e62043. PubMed ID: 23626768
[TBL] [Abstract][Full Text] [Related]
45. The blood-brain barrier is disrupted in Machado-Joseph disease/spinocerebellar ataxia type 3: evidence from transgenic mice and human post-mortem samples.
Duarte Lobo D; Nobre RJ; Oliveira Miranda C; Pereira D; Castelhano J; Sereno J; Koeppen A; Castelo-Branco M; Pereira de Almeida L
Acta Neuropathol Commun; 2020 Aug; 8(1):152. PubMed ID: 32867861
[TBL] [Abstract][Full Text] [Related]
46. Planning Future Clinical Trials for Machado-Joseph Disease.
Saute JAM; Jardim LB
Adv Exp Med Biol; 2018; 1049():321-348. PubMed ID: 29427112
[TBL] [Abstract][Full Text] [Related]
47. The autophagy-enhancing drug carbamazepine improves neuropathology and motor impairment in mouse models of Machado-Joseph disease.
Vasconcelos-Ferreira A; Carmo-Silva S; Codêsso JM; Silva P; Martinez ARM; França MC; Nóbrega C; Pereira de Almeida L
Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12763. PubMed ID: 34432315
[TBL] [Abstract][Full Text] [Related]
48. Compromised mitochondrial complex II in models of Machado-Joseph disease.
Laço MN; Oliveira CR; Paulson HL; Rego AC
Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
[TBL] [Abstract][Full Text] [Related]
49. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds.
Tang B; Liu C; Shen L; Dai H; Pan Q; Jing L; Ouyang S; Xia J
Arch Neurol; 2000 Apr; 57(4):540-4. PubMed ID: 10768629
[TBL] [Abstract][Full Text] [Related]
50. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.
Durcan TM; Kontogiannea M; Thorarinsdottir T; Fallon L; Williams AJ; Djarmati A; Fantaneanu T; Paulson HL; Fon EA
Hum Mol Genet; 2011 Jan; 20(1):141-54. PubMed ID: 20940148
[TBL] [Abstract][Full Text] [Related]
51. Variants in Genes of Calpain System as Modifiers of Spinocerebellar Ataxia Type 3 Phenotype.
Martins AC; Rieck M; Leotti VB; Saraiva-Pereira ML; Jardim LB
J Mol Neurosci; 2021 Sep; 71(9):1906-1913. PubMed ID: 34191270
[TBL] [Abstract][Full Text] [Related]
52. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
53. Polyglutamine-Independent Features in Ataxin-3 Aggregation and Pathogenesis of Machado-Joseph Disease.
Carvalho AL; Silva A; Macedo-Ribeiro S
Adv Exp Med Biol; 2018; 1049():275-288. PubMed ID: 29427109
[TBL] [Abstract][Full Text] [Related]
54. Trinucleotide expansion within the MJD1 gene presents clinically as spinocerebellar ataxia and occurs most frequently in German SCA patients.
Schöls L; Vieira-Saecker AM; Schöls S; Przuntek H; Epplen JT; Riess O
Hum Mol Genet; 1995 Jun; 4(6):1001-5. PubMed ID: 7655453
[TBL] [Abstract][Full Text] [Related]
55. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products.
Silva-Fernandes A; Costa Mdo C; Duarte-Silva S; Oliveira P; Botelho CM; Martins L; Mariz JA; Ferreira T; Ribeiro F; Correia-Neves M; Costa C; Maciel P
Neurobiol Dis; 2010 Oct; 40(1):163-76. PubMed ID: 20510362
[TBL] [Abstract][Full Text] [Related]
56. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains.
Fujigasaki H; Uchihara T; Koyano S; Iwabuchi K; Yagishita S; Makifuchi T; Nakamura A; Ishida K; Toru S; Hirai S; Ishikawa K; Tanabe T; Mizusawa H
Exp Neurol; 2000 Oct; 165(2):248-56. PubMed ID: 10993685
[TBL] [Abstract][Full Text] [Related]
57. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells.
Tsai HF; Tsai HJ; Hsieh M
Biochem Biophys Res Commun; 2004 Nov; 324(4):1274-82. PubMed ID: 15504352
[TBL] [Abstract][Full Text] [Related]
58. From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
Da Silva JD; Teixeira-Castro A; Maciel P
Neurotherapeutics; 2019 Oct; 16(4):1009-1031. PubMed ID: 31691128
[TBL] [Abstract][Full Text] [Related]
59. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
60. Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
Carmona V; Cunha-Santos J; Onofre I; Simões AT; Vijayakumar U; Davidson BL; Pereira de Almeida L
Mol Ther; 2017 Apr; 25(4):1038-1055. PubMed ID: 28236575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
